Solventum Corporation

Valuation Analysis

About the Company

Solventum Corporation en bref

Solventum Corporation (SOLV) is currently trading at 65,84 € with a market capitalization of 11,4 Md €. The trailing P/E ratio stands at 9.24x, with a forward P/E of 10.71x. The 52-week range spans from 54,44 € to 76,97 €; the current price is 14.5% below the yearly high. Year-over-year revenue growth stands at -3.0%. The net profit margin stands at 17.33%.

💰 Dividende

Solventum Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent Solventum Corporation (SOLV) au consensus : Acheter. L'objectif de cours moyen est de 71,69 €, soit un potentiel de +8.89% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 52,36 € à 87,27 €.

Solventum Corporation : la thèse d'investissement en détail

Solventum Corporation (SOLV) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Return on equity of 34.79% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 17.33%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue is contracting at -3% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valorisation en contexte

The PEG ratio at 1.22 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (5.15%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Solventum Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.